AP2014008147A0 - Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors - Google Patents

Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors

Info

Publication number
AP2014008147A0
AP2014008147A0 AP2014008147A AP2014008147A AP2014008147A0 AP 2014008147 A0 AP2014008147 A0 AP 2014008147A0 AP 2014008147 A AP2014008147 A AP 2014008147A AP 2014008147 A AP2014008147 A AP 2014008147A AP 2014008147 A0 AP2014008147 A0 AP 2014008147A0
Authority
AP
ARIPO
Prior art keywords
pyrimidines
pyrrolo
amino
substituted
novel
Prior art date
Application number
AP2014008147A
Other versions
AP3902A (en
Inventor
Paul Galatsis
Matthew Merrill Hayward
Jaclyn Henderson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014008147(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AP2014008147A0 publication Critical patent/AP2014008147A0/en
Application granted granted Critical
Publication of AP3902A publication Critical patent/AP3902A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
AP2014008147A 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors AP3902A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666299P 2012-06-29 2012-06-29
US201361820828P 2013-05-08 2013-05-08
PCT/IB2013/055039 WO2014001973A1 (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS

Publications (2)

Publication Number Publication Date
AP2014008147A0 true AP2014008147A0 (en) 2014-12-31
AP3902A AP3902A (en) 2016-11-17

Family

ID=49029142

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008147A AP3902A (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors

Country Status (32)

Country Link
US (2) US9156845B2 (en)
EP (2) EP3255049A1 (en)
JP (3) JP6189948B2 (en)
KR (1) KR20150027267A (en)
CN (2) CN105732639A (en)
AP (1) AP3902A (en)
AR (1) AR091628A1 (en)
AU (1) AU2013282869B2 (en)
BR (1) BR112014032913A2 (en)
CA (1) CA2878054C (en)
CL (1) CL2014003566A1 (en)
CO (1) CO7160063A2 (en)
CR (1) CR20140566A (en)
DO (1) DOP2014000303A (en)
EA (1) EA025186B1 (en)
ES (1) ES2637245T3 (en)
GE (1) GEP201706620B (en)
GT (1) GT201400301A (en)
HK (1) HK1204619A1 (en)
IL (1) IL236294A (en)
MD (1) MD20140130A2 (en)
MX (1) MX2014015769A (en)
NI (1) NI201400151A (en)
NZ (1) NZ702571A (en)
PE (1) PE20150153A1 (en)
PH (1) PH12014502886B1 (en)
SG (1) SG11201408044QA (en)
TN (1) TN2014000537A1 (en)
TW (1) TWI482774B (en)
UY (1) UY34883A (en)
WO (1) WO2014001973A1 (en)
ZA (1) ZA201409136B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN105732639A (en) 2012-06-29 2016-07-06 辉瑞大药厂 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
US8963597B1 (en) * 2013-10-02 2015-02-24 Nanya Technology Corporation Cross-domain enablement method and electronic apparatus
JP6487921B2 (en) 2013-12-17 2019-03-20 ファイザー・インク Novel 3,4-disubstituted-1H-pyrrolo [2,3-b] pyridines and 4,5-disubstituted-7H-pyrrolo [2,3-c] pyridazines as LRRK2 inhibitors
CN105940004B (en) * 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 Compound
ES2717757T3 (en) 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compounds
WO2015176010A1 (en) * 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN104086553B (en) * 2014-06-13 2016-04-27 南京药石科技股份有限公司 One prepares the method for 7-bromine imidazo [2,1-f] [1,2,4] triazine-4-amine
WO2016007540A2 (en) 2014-07-10 2016-01-14 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
PL3218378T3 (en) 2014-11-14 2020-10-19 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
KR102161364B1 (en) 2015-09-14 2020-09-29 화이자 인코포레이티드 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
FR3041640B1 (en) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOVEL PYRROLO [2,3-d] PYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR107032A1 (en) 2015-12-09 2018-03-14 Padlock Therapeutics Inc PAD4 BICYCLIC INHIBITORS
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
JP7101176B2 (en) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 5- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -5-azaspiro [2.5] octane-8-carboxylic acid derivative as a novel JAK kinase inhibitor
CN106831790B (en) * 2017-02-17 2019-07-26 四川大学华西医院 7H- pyrrolo- [2,3-d] pyrimidine derivatives
JP6728503B2 (en) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション Pharmaceutical composition for preventing or treating brain tumor containing as an active ingredient a compound capable of crossing the blood-brain barrier
KR20190131981A (en) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for use in preventing or treating Traumatic Brain Injury or stroke
KR101990739B1 (en) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier
KR20200023231A (en) * 2018-08-23 2020-03-04 재단법인 대구경북첨단의료산업진흥재단 Novel use of pyrimidine derivatives containing LRRK kinase inhibitors as active ingredients
KR101992059B1 (en) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier
EP3966209A4 (en) 2019-05-08 2023-01-04 Vimalan Biosciences, Inc. Jak inhibitors
MX2022001702A (en) 2019-08-08 2022-04-20 Vimalan Biosciences Inc Jak inhibitors.
CN115003300A (en) * 2019-09-25 2022-09-02 维玛兰生物科学公司 JAK inhibitors
JP2023514654A (en) * 2020-02-25 2023-04-06 ブイアイビー ブイゼットダブリュ Allosteric regulator of leucine-rich repeat kinase 2
CN111671757A (en) * 2020-07-16 2020-09-18 福建医科大学附属协和医院 Pharmaceutical application of 3- [4- (4-morpholinyl) -7H-pyrrolo [2,3-D ] pyrimidine-5-yl ] benzonitrile
CA3190782A1 (en) * 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
CA3202773A1 (en) * 2020-10-26 2022-05-05 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
WO2023039368A1 (en) * 2021-09-07 2023-03-16 Ptc Therapeutics, Inc. Methods for treating neurogenerative diseases
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP2890448B2 (en) 1988-04-26 1999-05-17 日産化学工業株式会社 Pyrazolopyridine mevalonolactones
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CA2011504C (en) 1989-03-07 1998-06-02 Kenji Ohmori Imidazoquinolone derivatives
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
JPH03271289A (en) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd Production of pyrazolopyridine derivative and dihydropyrazolopyridine derivative
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3130342B2 (en) 1991-10-04 2001-01-31 日産化学工業株式会社 Atherosclerotic intimal thickening inhibitor
JP3271289B2 (en) 1992-02-28 2002-04-02 スズキ株式会社 Valve drive for 4-cycle engine
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
ATE197051T1 (en) 1992-04-03 2000-11-15 Upjohn Co PHARMACEUTICALLY ACTIVE BICYCLIC HETEROCYCLIC AMINE
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH05310700A (en) 1992-05-12 1993-11-22 Sagami Chem Res Center Condensed pyridine-based mevalonolactone intermediate and its production
JPH0641114A (en) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd New mevalonolactones and its production
JPH06116239A (en) 1992-10-05 1994-04-26 Nissan Chem Ind Ltd 7-substituted-3, 5-dihydroxyhept-6-ynoic acid compounds
EP0665224A1 (en) 1992-10-16 1995-08-02 Nippon Soda Co., Ltd. Pyrimidine derivative
WO1994017197A1 (en) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTIBODY AGAINST β-AMYLOID OR DERIVATIVE THEREOF AND USE THEREOF
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (en) 1993-02-15 1994-08-18 Bayer Ag Heterocyclic substituted phenyl-cyclohexane-carboxylic acid derivatives
JP3119758B2 (en) 1993-02-24 2000-12-25 日清製粉株式会社 7-Azaindole derivative and antiulcer drug containing the same as active ingredient
JP3350739B2 (en) 1993-06-10 2002-11-25 コニカ株式会社 Method for developing black-and-white silver halide photographic materials
CN1102644A (en) 1993-11-11 1995-05-17 财团法人相模中央化学研究所 Condensed pyridine type mevalonolactone intermediate and process for its production
JPH07281365A (en) 1994-04-07 1995-10-27 Konica Corp Method for processing silver halide photographic sensitive material
DK0682027T3 (en) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative action
JP3448724B2 (en) 1995-11-29 2003-09-22 コニカ株式会社 Developer for silver halide photographic material and processing method thereof
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
ATE244719T1 (en) * 1996-03-15 2003-07-15 Novartis Pharma Gmbh N-7 HETEROCYCLYL-PYRROLO(2,3-D)PYRIMIDINES AND THEIR USE
JPH10213887A (en) 1996-11-26 1998-08-11 Konica Corp Treatment of black and white silver halide photographic sensitive material
US6413971B1 (en) * 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
EP0846981A1 (en) 1996-12-03 1998-06-10 Konica Corporation Method for processing black-and-white silver halide photographic light-sensitive material
JP3543249B2 (en) 1996-12-18 2004-07-14 コニカミノルタホールディングス株式会社 Processing method of black and white silver halide photographic material
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
PT1087970E (en) 1998-06-19 2004-06-30 Pfizer Prod Inc PYRIMIDINE COMPOUNDS 2,3-D | PYRIMIDINE
YU25500A (en) 1999-05-11 2003-08-29 Pfizer Products Inc. Process for the synthesis of nucleosite analogues
US6309811B2 (en) 1999-07-21 2001-10-30 Eastman Kodak Company Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler
KR100767146B1 (en) 2000-02-24 2007-10-15 워싱톤 유니버시티 Humanized Antibodies That Sequester Amyloid Beta Peptide
JP2001302515A (en) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd Poly(adp-ribose)polymerase inhibitor
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
KR20030062442A (en) 2000-12-22 2003-07-25 와이어쓰 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
AU2002315389A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AU2002339230A1 (en) 2002-03-08 2003-09-22 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
WO2004014368A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202463D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
AU2003279216A1 (en) 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10259382A1 (en) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidin-4-one derivatives, their preparation and use
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
MXPA05013770A (en) 2003-06-19 2006-03-08 Pfizer Prod Inc Nk1 antagonist.
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CA2555071A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
ES2337376T3 (en) 2004-04-01 2010-04-23 Eli Lilly And Company H3 HISTAMINE RECEIVING AGENTS, PREPARATION AND THERAPEUTIC USES.
CA2561724A1 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
WO2005116034A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
WO2005121175A2 (en) 2004-06-08 2005-12-22 Novartis Vaccines And Diagnostics Inc. Env polypeptide complexes and methods of use
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
CA2584489C (en) 2004-10-21 2014-07-22 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
DE102004054634A1 (en) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
JP2008531568A (en) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド Imidazonaphthyridine substituted with hydroxyalkyl
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
DE602006018301D1 (en) 2005-06-22 2010-12-30 Pfizer Prod Inc HISTAMINE-3 RECEPTOR ANTAGONISTS
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc INHIBITORS OF Akt ACTIVITY
JP5140600B2 (en) 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Azaindole inhibitors of Aurora kinase
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009539762A (en) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Tetralin antagonist of H3 receptor
US8163511B2 (en) 2006-03-14 2012-04-24 Cellzome Ag Methods for the identification of LRRK2 interacting molecules
WO2007124096A2 (en) 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
KR20090019848A (en) 2006-06-20 2009-02-25 노파르티스 아게 Biomarkers for the progression of alzheimer's disease
WO2008070908A1 (en) 2006-12-11 2008-06-19 Bionomics Limited Chemical compounds and processes
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
WO2008090429A1 (en) 2007-01-22 2008-07-31 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
FR2912744B1 (en) 2007-02-16 2012-09-07 Centre Nat Rech Scient PYRROLO-2,3-B-PYRIDINE COMPOUNDS, AZAIN-DOLES COMPOUNDS USEFUL IN THE SYNTHESIS OF THESE PYRROLO-2,3-B-PYRIDINE COMPOUNDS, METHODS OF MAKING THEM AND USES THEREOF.
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2152712B1 (en) 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
DE102007028515A1 (en) 2007-06-21 2008-12-24 Merck Patent Gmbh 6- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
WO2009000319A1 (en) 2007-06-22 2008-12-31 Schulz Hans M Manual input device
WO2009005730A1 (en) 2007-06-27 2009-01-08 Cornell University Transgenic animal models of parkinson's disease
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
KR20100074183A (en) 2007-09-14 2010-07-01 사노피-아벤티스 3-methyl-2-((2s)-2-(4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3h)-one as tau protein kinase inhibitor
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US8841319B2 (en) 2007-12-05 2014-09-23 Johannes Gutenberg-Universitat Mainz Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
ES2616255T3 (en) 2008-04-30 2017-06-12 National Health Research Institutes Condensed bicyclic pyrimidine compounds as aurora kinase inhibitors
DE102008025751A1 (en) 2008-05-29 2009-12-03 Merck Patent Gmbh New 4-(1H-pyrrolo(2,3-b)pyridin-3-yl)-pyridin-2-yl-amine derivatives are serine kinase modulators, useful to treat solid tumors, tumor growth, tumor metastasis, AIDS, occlusive neointimal lesions, arteriosclerosis, coronary artery disease
AR072008A1 (en) 2008-06-13 2010-07-28 Merck & Co Inc HETEROBICICLIC COMPOUNDS AS QUINASA P38 INHIBITION AGENTS
DE102008031517A1 (en) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
FR2935712A1 (en) 2008-09-05 2010-03-12 Ct Hospitalier Regional Univer METHOD FOR DETECTING THE DIFFERENTIAL EXPRESSION OF A MOLECULAR MARK SET ASSOCIATED WITH PARKINSON'S DISEASE
GB2463656B (en) 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20100175140A1 (en) 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
WO2010080712A2 (en) 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2210887A1 (en) 2009-01-14 2010-07-28 Isdin, S.A. Bis resorcinyl triazine derivatives as protecting agents against UV radiation
US20100273769A1 (en) 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease
WO2010093191A2 (en) 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
RU2011142182A (en) * 2009-03-19 2013-04-27 Медикал Рисерч Каунсил Текнолоджи COMPOUNDS
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20100116765A (en) 2009-04-23 2010-11-02 인제대학교 산학협력단 Methods to screen materials to inhibit parkinson's disease
DE102009019962A1 (en) 2009-05-05 2010-11-11 Merck Patent Gmbh 3 - ([1,2,3] triazol-4-yl) -pyrrolo [2,3-b] pyridine
ES2659725T3 (en) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
EP2483254B1 (en) 2009-09-29 2014-08-13 Glaxo Group Limited Novel compounds
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
KR101690358B1 (en) 2009-10-29 2017-01-09 제노스코 Kinase inhibitors
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
US20150018301A1 (en) * 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
BR112012011287B1 (en) 2009-11-13 2022-02-08 Genosco PYROLOPYRIMIDINE-DERIVED KINASE INHIBITOR COMPOUNDS, THEIR PHARMACEUTICAL FORMULATION AND THEIR USES
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
CA2986631C (en) 2009-12-21 2020-06-02 Samumed, Llc 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP5863058B2 (en) 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1H-imidazo [4,5-c] quinoline
US9303322B2 (en) 2010-05-24 2016-04-05 Integran Technologies Inc. Metallic articles with hydrophobic surfaces
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
KR101208198B1 (en) 2010-08-27 2012-12-04 인제대학교 산학협력단 Pharmaceutical composition for treating or preventing Parkinson's disease comprising compound having inhibitory effect of LRRK2 kinase activity
TW201305109A (en) 2010-09-02 2013-02-01 Glaxo Group Ltd Novel compounds
SG188302A1 (en) 2010-09-16 2013-04-30 Hutchison Medipharma Ltd Fused heteroaryls and their uses
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP5310700B2 (en) 2010-10-27 2013-10-09 パナソニック株式会社 LED package manufacturing system and resin coating method in LED package manufacturing system
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
US8815882B2 (en) 2010-11-10 2014-08-26 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
WO2012075046A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Assays and biomarkers for lrrk2
US20130338106A1 (en) 2011-02-28 2013-12-19 John A. McCauley Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
EA034193B1 (en) 2011-04-21 2020-01-15 Оригенис Гмбх Heterocyclic compounds as kinase inhibitors
WO2012143144A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012159079A1 (en) 2011-05-18 2012-11-22 The Parkinson's Institute Assay to determine lrrk2 activity in parkinson's disease
RU2637936C2 (en) 2011-05-23 2017-12-08 Элан Фармасьютикалз, Инк. Inhibitors of lrrk2 kinases activity
WO2012178015A2 (en) 2011-06-24 2012-12-27 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
RU2622104C2 (en) 2011-09-30 2017-06-13 Онкодизайн С.А. Macrocyclic lrrk2 kinase inhibitors
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2013166276A1 (en) 2012-05-02 2013-11-07 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
BR112014026952B1 (en) 2012-05-03 2022-03-15 Genentech, Inc Pyrazole aminopyrimidine derivatives and composition comprising them
CN105732639A (en) 2012-06-29 2016-07-06 辉瑞大药厂 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6116239B2 (en) 2012-12-28 2017-04-19 キヤノン株式会社 Subject information acquisition apparatus and subject information acquisition method
CN103518398B (en) 2013-03-21 2017-07-07 华为终端有限公司 Data transmission method, base station and user equipment
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
JP6487921B2 (en) 2013-12-17 2019-03-20 ファイザー・インク Novel 3,4-disubstituted-1H-pyrrolo [2,3-b] pyridines and 4,5-disubstituted-7H-pyrrolo [2,3-c] pyridazines as LRRK2 inhibitors
CN111772834B (en) 2014-03-21 2022-07-15 阿莱恩技术有限公司 Segmented orthodontic appliances with elastics

Also Published As

Publication number Publication date
CO7160063A2 (en) 2015-01-15
NZ702571A (en) 2017-02-24
ES2637245T3 (en) 2017-10-11
US9156845B2 (en) 2015-10-13
AP3902A (en) 2016-11-17
IL236294A (en) 2016-09-29
CN104395315B (en) 2016-08-17
CL2014003566A1 (en) 2015-04-10
TWI482774B (en) 2015-05-01
DOP2014000303A (en) 2015-03-15
PH12014502886A1 (en) 2015-02-23
MD20140130A2 (en) 2015-04-30
AR091628A1 (en) 2015-02-18
CA2878054C (en) 2018-09-11
GEP201706620B (en) 2017-02-10
JP2017226684A (en) 2017-12-28
SG11201408044QA (en) 2015-01-29
EA025186B1 (en) 2016-11-30
CA2878054A1 (en) 2014-01-03
EP3255049A1 (en) 2017-12-13
HK1204619A1 (en) 2015-11-27
PH12014502886B1 (en) 2015-02-23
EA201492125A1 (en) 2015-06-30
EP2867236A1 (en) 2015-05-06
AU2013282869B2 (en) 2015-12-24
KR20150027267A (en) 2015-03-11
UY34883A (en) 2014-01-31
TN2014000537A1 (en) 2016-03-30
CN104395315A (en) 2015-03-04
MX2014015769A (en) 2015-04-10
BR112014032913A2 (en) 2017-06-27
JP6462795B2 (en) 2019-01-30
US20150366874A1 (en) 2015-12-24
NI201400151A (en) 2015-06-05
TW201414736A (en) 2014-04-16
JP6189948B2 (en) 2017-08-30
ZA201409136B (en) 2016-08-31
CN105732639A (en) 2016-07-06
US9642855B2 (en) 2017-05-09
WO2014001973A1 (en) 2014-01-03
JP2015522002A (en) 2015-08-03
GT201400301A (en) 2015-06-02
AU2013282869A1 (en) 2015-01-15
US20140005183A1 (en) 2014-01-02
CR20140566A (en) 2015-01-09
JP2019073522A (en) 2019-05-16
EP2867236B1 (en) 2017-06-14
PE20150153A1 (en) 2015-02-05
IL236294A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AP3902A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
IL261282A (en) Purinone compounds as kinase inhibitors
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
HK1215253A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
CO6801740A2 (en) Pyrrolo [2,3-d] pyrimidine tropomyosin-related kinase inhibitors
HK1187905A1 (en) Substituted pyrimidinyl pyrroles active as kinase inhibitors
HK1199880A1 (en) Benzonitrile derivatives as kinase inhibitors
EP2788000A4 (en) Pyrrolopyrimidines as janus kinase inhibitors
HUE056365T2 (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
EP2758050A4 (en) Acyclic cyanoethylpyrazoles as janus kinase inhibitors
EP2706853A4 (en) Aminopyrimidines as syk inhibitors
ZA201209029B (en) Novel pyrimidine derivatives
IL232234A0 (en) Aminopyrimidine kinase inhibitors
IL228928A0 (en) Aminopyrimidine kinase inhibitors
HK1205106A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors syk
PT2694513E (en) Pyrazolo pyrimidine derivatives
HK1209740A1 (en) Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use --[23-d] pi3k
TH1401007889A (en) A novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidine as a LRRK2 inhibitor.